Rheumatoid arthritis following PEG-interferon-alfa-2a plus ribavirin treatment for chronic hepatitis C: A case report and review of the literature

BMC Research Notes

Volumn 6, Issue 1, 2013, Pages

  Cacopardo, Bruno ^a   Benanti, Francesco ^a   Pinzone, Marilia Rita ^a   Nunnari, Giuseppe ^a  

^a UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VIRUS;

ALPHA INTERFERON; ANTIVIRUS AGENT; AUTOANTIBODY; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; MACROGOL DERIVATIVE; PEGINTERFERON ALPHA2A; RECOMBINANT PROTEIN; RIBAVIRIN; VIRUS RNA;

ARTICLE; BIOSYNTHESIS; CASE REPORT; CHEMICALLY INDUCED DISORDER; CLASSIFICATION; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; GENETICS; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOLOGY; MALE; MIDDLE AGED; PATHOLOGY; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POLYETHYLENE GLYCOLS; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; TREATMENT OUTCOME;

EID: 84886548895     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-6-437     Document Type: Review

References (25)

1. Natural history of hepatitis C. Alberti A, Chemello L, Benvegnu L, J Hepatol 1999 31 17 24 10622555 (Pubitemid 30002686)
2. Hepatocellular carcinoma in HIV-infected patients: check early, treat hard. Berretta M, Garlassi E, Cacopardo B, Cappellani A, Guaraldi G, Cocchi S, De Paoli P, Lleshi A, Izzi I, Torresin A, Di Gangi P, Pietrangelo A, Ferrari M, Bearz A, Berretta S, Nasti G, Di Benedetto F, Balestreri L, Tirelli U, Ventura P, Oncologist 2011 16 9 1258 1269 10.1634/theoncologist.2010-0400 21868692
3. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. Craxì A, Pawlotsky M, Wedemeyer H, Bjoro K, Flisiak R, Forns X, Mondelli M, Peck-Radosavljevic M, Rosenberg W, Sarrazin C, Jacobson I, Dusheiko G, J Hepatol 2011 55 2 245 264 21371579
4. Side effects of therapy of hepatitis C and their management. Fried MW, Hepatology 2002 36 237 S244 12407599
5. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Welsch C, Jesudian A, Zeuzem S, Jacobson I, Gut 2012 61 S1 36 46 Erratum in: Gut. 2012;61(8):1145 22504918
6. MicroRNA-122: a therapeutic target for hepatitis C virus (HCV) infection. Nunnari G, Schnell MJ, Front Biosci (Schol Ed) 2011 3 1032 1037 21622252
7. Hepatitis C and interferon induced thyroiditis. Tomer Y, J Autoimmun 2010 34 3 322 326 10.1016/j.jaut.2009.11.008 20022216
8. Leucocyte interferon-alpha retreatment for chronic hepatitis C patients previously intolerant to other interferons. Cacopardo B, Benanti F, Brancati G, Romano F, Nunnari A, J Viral Hepat 1998 5 5 333 339 10.1046/j.1365-2893.1998. 00113.x 9795917 (Pubitemid 28440328)
9. Potential mechanisms of interferon-alpha induced autoimmunity. Conrad B, Autoimmunity 2003 36 8 519 523 10.1080/08916930310001602137 14984029 (Pubitemid 37498248)
10. Autoimmunity induced by interferon-alpha therapy for chronic viral hepatitis. Dumoulin FL, Leifeld L, Sauerbruch T, Spengler U, Biomed Pharmacother 1999 53 5-6 242 254 10424246
11. Rheumatoid arthritis following a treatment with IFN-alpha/ribavirin against HCV infection. Izumi Y, Komori A, Yasunaga Y, Hashimoto S, Miyashita T, Abiru S, Yatsuhashi H, Ishibashi H, Migita K, Intern Med 2011 50 9 1065 1068 10.2169/internalmedicine.50.4790 21532235
12. Rheumatoid arthritis probably induced by pegylated interferon in a patient with chronic hepatitis C. Sood A, Midha V, Sood N, Indian J Gastroenterol 2004 23 28 29 15106716 (Pubitemid 38477974)
13. Prolonged Treatment with Interferon Alpha and Peginterferon Induces Rheumatoid Artrhitis Syndrome and Erythema Nodosum. Ionescu C, Micu L, Constantinescu I, Hortopan M, Ursaciuc C, Voiculescu M, J Gastrointestin Liver Dis 2008 17 2 211 212 18568145 (Pubitemid 351930772)
14. Development of Anti-CCP-positive Rheumatoid Arthritis Following Pegylated Interferon-α2a Treatment for Chronic Hepatitis C Infection. Yang D, Arkfeld D, Fong TL, J Rheumatol 2010 37 1777 10.3899/jrheum.100092 20675854
15. Hepatitis C virus related arthritis: characteristics and response to therapy with interferon alpha. Zuckerman E, Keren D, Rozenbaum M, Toubi E, Slobodin G, Tamir A, Naschitz JE, Yeshurun D, Rosner I, Clin Exp Rheumatol 2000 18 579 584 10.1007/s100510070005 11072597
16. Current practice of hepatitis C treatment in Southern Italy. Stroffolini T, Spadaro A, Guadagnino V, Cosentino S, Fatuzzo F, Galdieri A, Cacopardo B, Scalisi I, Sapienza M, Russello M, Scifo G, Frugiuele P, Foti G, Almasio PL, Gr.E. Ca.S. Hospitals' Collaborating Group, Dig Liver Dis 2010 42 11 822 825 10.1016/j.dld.2010.03.020 20435532
17. Diagnostic and therapeutical role of vitamin D in chronic hepatitis C virus infection. Cacopardo B, Camma C, Petta S, Pinzone MR, Cappellani A, Zanghi A, Nicolosi A, Nunnari G, Front Biosci (Elite Ed) 2012 4 1276 1286 22201953
18. Leukocyte interferon alpha early retreatment for Child A HCV genotype 1b-infected cirrhotics intolerant to pegylated interferons. Cacopardo B, Nunnari G, Benanti F, Cappellani A, Onorante A, Caltabiano E, Russo R, Infection 2009 37 3 210 215 10.1007/s15010-008-8164-2 19139808
19. The use of peginterferon in monotherapy or in combination with ribavirin for the treatment of acute hepatitis C. Nunnari G, Montineri A, Portelli V, Savalli F, Fatuzzo F, Cacopardo B, Eur Rev Med Pharmacol Sci 2012 16 8 1013 1016 22913149
20. Comparison of adverse effects related to pegylated interferon-based therapy for patients with chronic hepatitis B and chronic hepatitis C in Taiwan. Yang JF, Kao YH, Dai CY, Huang JF, Hsieh MY, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chuang WL, Yu ML, Hepatol Int 2010 4 4 732 740 10.1007/s12072-010-9208-0 21286344
21. Microbial translocation in chronic liver diseases. Pinzone MR, Celesia BM, Di Rosa M, Cacopardo B, Nunnari G, Int J Microbiol 2012 2012 694629 22848224
22. Hepatitis C virus-related skin diseases. Doutre MS, Arch Dermatol 1999 135 11 1401 1403 10.1001/archderm.135.11.1401 10566842
23. Interferon alpha accelerates murine SLE in a T cell-dependent manner. Liu Z, Bethunaickan R, Huang W, Arthritis Rheum 2011 63 1 219 229 10.1002/art.30087 20954185
24. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Krumbholz M, Faber H, Steinmeyer F, Hoffmann LA, Kümpfel T, Pellkofer H, Derfuss T, Ionescu C, Starck M, Hafner C, Hohlfeld R, Meinl E, Brain 2008 131 1455 1463 10.1093/brain/awn077 18474519 (Pubitemid 351806460)
25. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, Pietrapertosa D, Morelli A, Ferraccioli G, J Rheumatol 2008 35 1256 1264 18528969 (Pubitemid 352000768)